touchTALKS Investigating KRASG12C inhibitors: How might they improve outcomes for patients with solid tumours?
Prof. Tony Mok discusses the role of KRAS mutations in solid tumours and the impact of KRASG12C inhibitors on patient outcomes.
Investigating the role of KRAS mutations in solid tumours
Prof. Tony Mok discusses KRAS mutations in solid tumours, with a focus on the KRASG12C mutation and its impact on patient outcomes.
view bio and disclosures 1/3 Next ChapterTargeting the KRASG12C mutation in clinical practice
Prof. Tony Mok summarizes the available and emerging direct KRASG12C inhibitors and reviews the latest efficacy and safety data.
view bio and disclosures 2/3 Next ChapterTackling resistance to KRAS-targeted therapies
Prof. Tony Mok discusses the mechanisms of resistance to direct KRASG12C inhibitors and reviews the latest developments in potential inhibitor combinations to overcome resistance.
view bio and disclosures 3/3 Leave FeedbackOverview & Learning Objectives
Overview
In this activity, lung cancer expert Prof. Tony Mok considers the role of KRAS mutations in solid tumours, particularly non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), and explores how KRASG12C inhibitors are likely to impact patient outcomes.
This activity is provided by touchIME.
Learning Objectives
After watching this activity, participants should be better able to:
- Describe the role of KRAS in tumourigenesis and the implications of the KRASG12C mutation for patients with solid tumours
- Evaluate the efficacy and safety of KRASG12C inhibitors in advanced and metastatic KRAS-mutated solid tumours
- Formulate strategies to overcome intrinsic or acquired resistance to KRASG12C-directed therapies
Faculty & Disclosures
Prof. Tony Mok
Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
Prof. Tony Mok is the Li Shu Fan professor and chairman of the Department of Clinical Oncology at The Chinese University of Hong Kong, Hong Kong. read more
Prof. Mok’s main research interests are biomarkers and molecular targeted therapies in lung cancer. He was the principal investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), the first study to confirm the application of precision medicine for advanced lung cancer. Prof. Mok has also led and co-led multiple international phase III trials, including the FASTACT-2, PROFILE 1014, IMPRESS, ARCHER 1050, ALEX, AURA3 and KEYNOTE-042.
Prof. Mok has received numerous awards for his work. In 2020, he received the 6th Kobayashi Foundation Award, the Giant of Cancer Care 2020 and the SingTao Hong Kong Leader of the Year 2020 Award. He also received the ESMO Lifetime Achievement Award in 2018, and in 2017, he received the Fellowship of the American Society of Clinical Oncology (FASCO), Paul Bunn Jr Scientific Award, National Science and Technology Progress Award and the CSCO Annual Achievement Award. Prof. Mok is one of the “Highly Cited Researchers” named by Clarivate Analytics for four consecutive years from 2018 to 2021.
Prof. Tony Mok discloses: Advisory board or panel fees from AbbVie, ACEA Pharma, Amgen, AstraZeneca, Berry Oncology, Blueprint Medicines Corporation, Boehringer Ingelheim, Bristol Myers Squibb, C4 Therapeutics, Covidien LP, CStone Pharmaceuticals, Curio Science, D3 Bio, Daiichi Sankyo, Eisai, Eli Lilly and Company, G1 Therapeutics Inc., Gilead Sciences Inc., Gritstone bio, Guardant Health, Hengrui Therapeutics Inc., HUTCHMED, Ignyta, Incyte Corporation, Inivata Ltd., IQVIA, Janssen Pharmaceuticals, Loxo Oncology Inc., Lunit, Merck Serono, Merck Sharp & Dohme Ltd., Mirati Therapeutics Inc., Novartis, OrigiMed, Pfizer, Puma Biotechnology Inc., Roche/Genentech, Sanofi-Aventis R&D, SFJ Pharmaceuticals Inc., Takeda, Vertex Pharmaceuticals, Virtus Medical Group and Yuhan. Board of director roles in AstraZeneca PLC, HutchMed and Lunit USA Inc. Consultancy fees from AbbVie, ACEA Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, AstraZeneca, BeiGene, Berry Oncology, Blueprint Medicines Corporation, Boehringer Ingelheim, Bristol Myers Squibb, C4 Therapeutics, Covidien LP, CStone Pharmaceuticals, Curio Science, D3 Bio, Daiichi Sankyo, Eisai, Elevation Oncology, Eli Lilly and Company, Gilead Sciences Inc., Gritstone bio, Guardant Health, Hengrui Therapeutics Inc., Ignyta, Incyte Corporation, Inivata, IQVIA, Janssen Pharmaceuticals, Loxo Oncology, Lucence Health Inc., Lunit, Merck Serono, Mirati Therapeutics Inc., MoreHealth, MSD, Novartis, OrigiMed, OSE Immunotherapeutics, Pfizer, Puma Biotechnology Inc., Qiming Development (HK) Ltd., Roche Pharmaceuticals, Sanofi-Aventis, SFJ Pharmaceutical Ltd., Takeda Pharmaceuticals HK Ltd., Vertex Pharmaceuticals and Yuhan. Grants/research support from AstraZeneca, Bristol Myers Squibb, G1 Therapeutics, Merck Serono, MSD, Novartis, Pfizer, Roche Pharmaceuticals, SFJ Pharmaceutical Ltd., Takeda and XCovery. Speaker fees from ACEA Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Daz Group, Eli Lilly and Company, Janssen Pharmaceuticals, Lianyihui Liangyihui Network Technology Co Ltd., Lucence Health Inc., MD Health Brazil, Merck Pharmaceuticals HK Ltd., Merck Sharp & Dohme Ltd., Novartis, OrigiMed, Pfizer, Roche Pharmaceuticals/Diagnostics/Foundation, Sanofi-Aventis, Taiho, Takeda Oncology. Stock shares in Act Genomics-Sanomics Group, Aurora Tele-Oncology and HutchMed.
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
